Increased nitric oxide deactivation by polymorphonuclear leukocytes in patients with intermittent claudication.
OBJECTIVE
Local activation of polymorphonuclear leukocytes (PMNLs) is considered an important aspect of the pathogenesis of intermittent claudication, although concrete mechanisms of their effects on circulatory homeostasis in peripheral atherosclerotic disease remain unclear. This study evaluated the ability of PMNLs to deactivate nitric oxide (NO), a key regulator of regional circulation, as a possible factor determining PMNL involvement into ischemic disorders in patients who have intermittent claudication before and after vascular reconstruction.


METHODS
A total of 57 patients who had peripheral occlusive disease in an aortofemoral segment before surgical treatment (group 1) and 65 patients who had similar occlusive lesions and other clinical and demographic data 6 to 12 months after undergoing inflow vascular reconstruction (group 2) were examined. All patients from group 2 had anatomically patent grafts; their satisfaction and level of function after surgical treatment were assessed by a five-point questionnaire. The sex- and age-matched control group included 35 subjects. NO activity was bioassayed by measuring its ability to increase cyclic guanosine monophosphate (cGMP) accumulation in rat fetal lung-cultured fibroblasts (RFL-6 cells). The ability of PMNLs to deactivate NO was characterized as the percent decrease in NO-induced cGMP accumulation in RFL-6 cells.


RESULTS
Stimulated PMNLs caused inhibition of the activity of authentic NO; accumulation of cGMP induced by sodium nitroprusside was not affected. PMNLs from patients with peripheral atherosclerotic disease either before or after vascular reconstruction had a more marked capacity of NO inactivating than the cells from healthy subjects. For both groups of patients, levels of PMNL-induced NO deactivation were higher for patients with diabetes, and especially both diabetes and arterial hypertension. For both groups of patients, there was no correlation between levels of PMNL-induced NO deactivation and resting ankle-brachial indexes (ABIs). In contrast, close correlation was revealed between levels of PMNL-induced NO deactivation and postexercise ABIs and percent decrease in resting ABIs after exercise in patients evaluated either before or after surgical treatment.


CONCLUSIONS
The ability of stimulated PMNLs to deactivate NO is elevated in peripheral occlusive disease and may be implicated in the pathogenesis of intermittent claudication. In patients who underwent successful recanalization of magistral arteries, levels of PMNL-induced NO deactivation remained higher than in control subjects. The increase in the ability of PMNL to deactivate NO positively correlated to ABI decreases after exercise in patients with peripheral occlusive disease either before or after surgical treatment.
Akopov
S E
SE
Department of Vascular Surgery, Republican Medical Center Armenia.
Pogossian
S S
SS
Toromanian
E N
EN
Grigorian
G G
GG
Gabrielian
E S
ES
D000818:Animals; D001018:Aortic Diseases / Q000378:metabolism / Q000503:physiopathology / Q000601:surgery; D001161:Arteriosclerosis / Q000378:metabolism / Q000503:physiopathology / Q000601:surgery; D001775:Blood Circulation / Q000502:physiology; D001794:Blood Pressure; D016022:Case-Control Studies; D002478:Cells, Cultured; D006152:Cyclic GMP / Q000378:metabolism; D003920:Diabetes Mellitus / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D005263:Femoral Artery / Q000378:metabolism / Q000503:physiopathology / Q000601:surgery; D005347:Fibroblasts / Q000201:enzymology; D006706:Homeostasis / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000378:metabolism / Q000503:physiopathology; D007383:Intermittent Claudication / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology / Q000601:surgery; D007511:Ischemia / Q000503:physiopathology; D008168:Lung / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D018375:Neutrophil Activation; D009504:Neutrophils / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism*; D009599:Nitroprusside / Q000494:pharmacology; D017060:Patient Satisfaction; D016491:Peripheral Vascular Diseases / Q000378:metabolism / Q000503:physiopathology / Q000601:surgery; D051381:Rats; D014654:Vascular Patency
D009599:Nitroprusside; D009569:Nitric Oxide; D006152:Cyclic GMP